A researcher at the University of Houston has received a $100,000 grant to investigate adherence to oral disease-modifying therapies (DMTs) among people with multiple sclerosis (MS), and correlations between adherence patterns and disease outcomes over time. The one-year grant from the Agency for Healthcare Research and Quality was awarded…
A new collaboration between Arterys and Combinostics seeks to bring comprehensive artificial intelligence (AI) imaging solutions to the diagnosis and care of patients with multiple sclerosis (MS) and other neurological diseases. Under the partnership, Arterys will include Combinostics’ AI-powered cNeuro on its medical imaging cloud AI platform…
The Multiple Sclerosis Society of Canada is urging that all provinces and territories in Canada offer COVID-19 booster vaccines to at-risk populations, including people who are moderately to severely immunocompromised and multiple sclerosis (MS) patients. In letters sent earlier this month, in collaboration with 11 other health charities, the…
The number of lesions affecting the cerebellum — a brain region responsible for coordinating voluntary movements and motor skills such as balance, coordination, and posture — predicts manual dexterity getting worse in people with relapsing-remitting multiple sclerosis (RRMS), according to a retrospective analysis. The study, “Cerebellar pathology and…
Sanofi Genzyme has extended its collaboration with Koneksa to bring digital measures into its Phase 3 trials of tolebrutinib, an investigational therapy for relapsing and progressive forms of multiple sclerosis (MS). Through this joint effort, Koneksa’s digital biomarkers were applied to clinical trials of Parkinson’s…
The Scottish Medicines Consortium (SMC) has recommended that Ponvory (ponesimod) be offered through the National Health Service (NHS) Scotland to people with active, relapsing forms of multiple sclerosis (MS). The decision means that the oral therapy will be available at low or no cost to patients with clinically isolated syndrome (CIS),…
Numares has signed an exclusive licensing agreement with Oxford University Innovation to develop and commercialize a panel of biomarkers that identify disease progression in people with multiple sclerosis (MS). Specifically, the company aims to create a tool that detects early signs of conversion from relapsing remitting…
New preclinical data continues to support the potential of Cyxone’s investigational plant-derived peptide T20K for the treatment of multiple sclerosis (MS). In a collaboration with its academic partner, the Medical University of Vienna, Cyxone has shown that a combination of T20K plus an activator of the kappa…
The U.S. Patent and Trademark Office will grant Medsenic a patent covering the use of Arscimed, its investigational formulation of arsenic trioxide, for the treatment of relapsing-remitting multiple sclerosis (RRMS). Once issued, the patent will protect Arscimed’s use for this indication until 2037. This will add to the already…
Innodem Neurosciences is teaming up with Novartis Canada on a breakthrough clinical trial to evaluate if Innodem’s digital biomarker eye-tracking technology can monitor disease progression in people with multiple sclerosis (MS). The trial will test Innodem’s “easy-to-use, affordable technology,” which works using visible light, with no special infrared…
The National Institute for Health and Care Excellence (NICE) will not recommend that Ponvory (ponesimod) be added to the National Health Service (NHS) of England and Wales for people with active, relapsing forms of multiple sclerosis (MS). The provisional decision, made because Ponvory was not found to be…
Immunic Therapeutics has enrolled the first patient in a Phase 2 clinical trial testing its oral therapy candidate IMU-838 for the treatment of progressive multiple sclerosis (MS). The trial, CALLIPER (NCT05054140), is expected to run in parallel to the company’s two identically-designed Phase 3 trials, dubbed…
A partnership will allow NervGen to use Imeka‘s proprietary biomarker imaging technology to precisely measure changes in the brain and spinal cord in its upcoming clinical trials, including a study of NVG-291 in people with multiple sclerosis (MS) NervGen plans to initiate Phase 1b/2 trials into its lead candidate for neural…
The Accessible Product Design Alliance has released a statement calling for changes in products and packaging design to assure equal accessibility among consumers, including those with disabling disorders such as multiple sclerosis (MS). Composed of 11 nonprofit health consumer organizations in Australia and New Zealand — including MS…
Temedica, a Munich-based digital health company, has joined efforts with Roche to launch a free mobile app that aims to improve care for people with multiple sclerosis (MS) living in Germany. Available in German only, the Brisa app will make a record of individual disease progression in…
Belong.Life has launched an app that allows health professionals to build and manage their own online communities of multiple sclerosis (MS) patients. Called i-Belong – Connecting Communities, the app offers to healthcare providers, pharmaceuticals, and patient advocacy and other groups a platform to effectively and efficiently educate…
Moderate-to-severe bowel dysfunction was detected in 14.5% of adult people with multiple sclerosis (MS), an Italian study reports. The prevalence of bowel dysfunction was increased in women and in patients with progressive forms of MS, higher disability, older age, and longer disease duration. Despite the prevalence of bowel dysfunction…
Meeting people and dating is challenging for people with multiple sclerosis (MS), but the experience of dating is highly personal and influenced by past experiences and beliefs, a small study reveals. The study, “Dating with a Diagnosis: The Lived Experience of People with Multiple Sclerosis,” was published in…
Jazz Pharmaceuticals is planning to open a third Phase 3 clinical trial of Sativex (nabiximols), an oral spray that contains cannabis extracts, as an add-on treatment for people with multiple sclerosis (MS) and spasticity, the company announced. Set to start this year, the RELEASE MSS5…
A natural, small molecule called 3-HKA) has shown potent anti-inflammatory activity in lab tests and mouse models of immune-related diseases, a study found. The findings suggest that molecules that mimic 3-HKA (3-hydroxy-L-kynurenamine) may serve as broad-acting therapeutics to protect against inflammation in several autoimmune and inflammatory diseases, including multiple…
Actively taking steps to cope with the chronic stress of multiple sclerosis (MS) — from keeping a sense of humor to seeking emotional and tangible support — can help to improve patients’ quality of life, a small questionnaire-based study from Poland suggests. The study, “The Role of…
Three scientists in the U.K. were given awards by the International Progressive MS Alliance that will support projects aiming to explore new approaches to treating progressive forms of multiple sclerosis (MS). The three are among this year’s 19 winners of the alliance’s Research Challenge Awards, which totaled £1.2 million…
MediciNova announced that it will be given a U.S. patent covering the use of ibudilast (MN-166) in treating eye disease. This oral medication aims to lessen inflammation, including that of progressive multiple sclerosis (MS). Specifically, it will cover ibudilast’s use in treating injury or damage to the macula —…
Sativex (nabiximols), an oral spray that contains cannabis extracts, was found effective as an add-on therapy for easing spasticity in adult multiple sclerosis (MS) patients who failed to respond to other anti-spastic treatments, a real-world study from Belgium reports. Overall, about 74% patients reported easing of spasticity — muscle stiffness or…
The Multiple Sclerosis Society of Canada has granted its International Progressive MS Alliance (Alliance) Research Challenge Awards to 19 researchers for their work on progressive forms of multiple sclerosis (MS). Among them is Jennifer Gommerman, PhD, a professor at the University of Toronto, in Canada, who will use…
A home-based rehabilitation program can help ease fatigue, improve motor and cognitive function, and promote better quality of life in people with relapsing-remitting multiple sclerosis (RRMS), a small clinical trial has found. While a structured supervised exercise program was better at improving fatigue and health-related quality of life, the…
BurnAlong and the Shepherd Center, a leading rehabilitation hospital in the U.S., have established a partnership to bring tailored rehabilitation classes to people with multiple sclerosis (MS) and other neuromuscular diseases worldwide. The video classes, designed by clinicians, therapists, and wellness professionals at the Shepherd Center, based in Atlanta,…
A clinical trial investigating patient-derived stem cell transplants for the treatment of people with severe relapsing forms of multiple sclerosis (MS) has enrolled a patient in Minnesota. The patient was enrolled at the University of Minnesota Medical School, one of two trial sites in the state. An additional 18…
MindMaze’s animated ‘games,’ designed to aid in recovering motor and cognitive skills in people with neurological disabilities, such as multiple sclerosis (MS), will now be more widely available to patients worldwide. The brain technology company announced four new partnerships that will enable patients in Latin America, the Middle East,…
The National Institute for Health and Care Excellence (NICE) has maintained its initial draft recommendation and will not recommend that Zeposia (ozanimod) be added to the National Health Service (NHS) of England and Wales. This final decision on the cost effectiveness of the oral therapy means Zeposia will…
Get regular updates to your inbox.
